Published in Oncologist on July 01, 2007
Identifying better surgical candidates among recursive partitioning analysis class 2 patients who underwent surgery for intracranial metastases. World Neurosurg (2013) 2.02
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol (2015) 1.92
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neuro-oncological multidisciplinary teams. Childs Nerv Syst (2010) 1.38
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol (2009) 1.37
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol (2012) 1.32
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett (2010) 1.06
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol (2009) 1.02
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res (2015) 1.01
Effects of the AT1 receptor antagonist L-158,809 on microglia and neurogenesis after fractionated whole-brain irradiation. Radiat Res (2010) 1.00
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer (2010) 0.98
Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. Cancer Res (2012) 0.96
Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view. Eur J Med Res (2009) 0.93
The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. Sci Rep (2013) 0.93
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst (2015) 0.92
Future directions in treatment of brain metastases. Surg Neurol Int (2013) 0.91
Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases. BMC Cancer (2014) 0.90
STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget (2015) 0.89
Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget (2015) 0.88
Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. Br J Cancer (2013) 0.88
Palliative stereotactic-endoscopic third ventriculostomy for the treatment of obstructive hydrocephalus from cerebral metastasis. Surg Neurol Int (2011) 0.88
Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther (2013) 0.87
Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro Oncol (2016) 0.87
The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol (2014) 0.86
Functional role of endothelial adhesion molecules in the early stages of brain metastasis. Neuro Oncol (2013) 0.86
Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles. ScientificWorldJournal (2012) 0.85
Molecular interactions in the development of brain metastases. Int J Mol Sci (2013) 0.85
Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both. Radiat Oncol (2014) 0.85
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2014) 0.85
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget (2015) 0.85
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. Proc Natl Acad Sci U S A (2014) 0.84
Three-fraction CyberKnife radiotherapy for brain metastases in critical areas: referring to the risk evaluating radiation necrosis and the surrounding brain volumes circumscribed with a single dose equivalence of 14 Gy (V14). J Radiat Res (2013) 0.84
Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. J Control Release (2013) 0.83
Brain metastasis in pancreatic cancer. Int J Mol Sci (2013) 0.82
AT1 receptor antagonism does not influence early radiation-induced changes in microglial activation or neurogenesis in the normal rat brain. Radiat Res (2011) 0.82
Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol (2008) 0.81
In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. Front Oncol (2013) 0.81
Survival and recurrence for patients undergoing surgery of skull base intracranial metastases. J Neurol Surg B Skull Base (2013) 0.81
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain. Clin Cancer Res (2013) 0.80
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer. Oncotarget (2016) 0.80
Development and characterization of a clinically relevant mouse model of melanoma brain metastasis. Pigment Cell Melanoma Res (2013) 0.79
Patients undergoing surgery of intracranial metastases have different outcomes based on their primary pathology. Neurol Res (2013) 0.79
Molecular classification of brain tumor biopsies using solid-state magic angle spinning proton magnetic resonance spectroscopy and robust classifiers. Int J Oncol (2008) 0.79
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget (2016) 0.79
Rare incidence of a diffuse brain metastatic carcinoma: A case report. Oncol Lett (2014) 0.78
Involved field radiation therapy after surgical resection of solitary brain metastases--mature results. Neuro Oncol (2013) 0.78
Brain metastases in gastrointestinal cancers: is there a role for surgery? Int J Mol Sci (2014) 0.77
Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation. Cureus (2015) 0.77
Stereotactic radiosurgery for brain metastases from malignant melanoma. Surg Neurol Int (2015) 0.76
Hyaluronan expression in primary and secondary brain tumors. Ann Transl Med (2015) 0.76
MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. Int J Mol Sci (2014) 0.76
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis. PLoS One (2016) 0.76
TNF-α enhancement of CD62E mediates adhesion of non-small cell lung cancer cells to brain endothelium via CD15 in lung-brain metastasis. Neuro Oncol (2015) 0.76
[Spinal cord compression due to metastases]. Pan Afr Med J (2014) 0.75
Intraventricular metastases from small cell carcinoma of the lung. BMJ Case Rep (2012) 0.75
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci (2016) 0.75
State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. Transl Lung Cancer Res (2016) 0.75
Feasibility of simultaneous integrated boost with forward intensity-modulated radiation therapy for multiple brain metastases. Contemp Oncol (Pozn) (2014) 0.75
The Value of the History and Physical for Patients with Newly Diagnosed Brain Metastases Considering Radiosurgery. Front Oncol (2016) 0.75
Combined 3 Tesla MRI Biomarkers Improve the Differentiation between Benign vs Malignant Single Ring Enhancing Brain Masses. PLoS One (2016) 0.75
Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center. J Cancer Res Clin Oncol (2012) 0.75
Survival patterns of 5750 SRS-treated brain metastasis patients as a function of the number of lesions. World Neurosurg (2017) 0.75
[Radiotherapy of singular brain metastases]. Wien Med Wochenschr (2010) 0.75
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys (2002) 3.21
Charged particles in radiation oncology. Nat Rev Clin Oncol (2009) 2.78
Results of multimodality treatment for 141 patients with brain arteriovenous malformations and seizures: factors associated with seizure incidence and seizure outcomes. Neurosurgery (2002) 2.37
Patient study of in vivo verification of beam delivery and range, using positron emission tomography and computed tomography imaging after proton therapy. Int J Radiat Oncol Biol Phys (2007) 2.33
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol (2004) 2.24
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
Radiosurgery and radiotherapy: observations and clarifications. J Neurosurg (2004) 2.04
Radiation optic neuropathy after proton beam therapy for optic nerve sheath meningioma. J Neuroophthalmol (2013) 2.01
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Primary CNS lymphoma. J Clin Oncol (2006) 1.86
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol (2002) 1.74
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res (2006) 1.67
Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. J Neurosurg (2003) 1.63
Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys (2004) 1.58
The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res (2002) 1.57
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol (2009) 1.51
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol (2010) 1.40
Green eggs and ham: Strategies to address the growing phenomenon of selling a medical school's name. Acad Med (2014) 1.38
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol (2009) 1.37
Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol (2005) 1.36
Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg (2006) 1.28
Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol (2005) 1.28
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol (2010) 1.19
Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev (2007) 1.17
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol (2008) 1.13
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.13
Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res (2013) 1.10
Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys (2011) 1.10
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol (2009) 1.10
In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology (2002) 1.09
The accuracy of predicting survival in individual patients with cancer. J Neurosurg (2013) 1.08
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.07
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.04
Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry (2013) 1.00
Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus (2007) 0.99
Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg (2005) 0.99
Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J Neuropathol Exp Neurol (2009) 0.97
Sociodemographic indicators and risk of brain tumours. Int J Epidemiol (2003) 0.97
Metastatic epidural spinal cord compression: update on management. Semin Oncol (2006) 0.96
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol (2008) 0.94
Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. Head Neck (2009) 0.92
The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist (2002) 0.92
Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab (2007) 0.91
Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract (2008) 0.90
Low-grade gliomas. Oncologist (2014) 0.90
Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys (2005) 0.88
Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol (2008) 0.87
Technological advances in radiation oncology for central nervous system tumors. Semin Radiat Oncol (2009) 0.86
Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg (2009) 0.86
Radiation Treatment for WHO Grade II and III Meningiomas. Front Oncol (2013) 0.86
Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys (2009) 0.85
Radiation therapy in acromegaly. Rev Endocr Metab Disord (2008) 0.84
Planned two-fraction proton beam stereotactic radiosurgery for high-risk inoperable cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys (2011) 0.84
Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer (2005) 0.84
Occupational exposure to magnetic fields and the risk of brain tumors. Neuro Oncol (2009) 0.84
Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults. Am J Epidemiol (2006) 0.82
The relationship between occlusive hyperemia and complications associated with the radiosurgical treatment of arteriovenous malformations: report of two cases. Neurosurgery (2004) 0.82
Radiosurgery plus whole-brain radiation therapy for brain metastases. JAMA (2006) 0.82
Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery (2003) 0.81
Proton stereotactic radiosurgery for the treatment of benign meningiomas. Int J Radiat Oncol Biol Phys (2010) 0.81
Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer (2015) 0.81
Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol (2013) 0.81
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol (2009) 0.80
Comments about the prospective randomized trial by Aoyama et al. Surg Neurol (2006) 0.80
Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Int J Radiat Oncol Biol Phys (2012) 0.80
Proton beam radiation therapy. Cancer Invest (2006) 0.80
Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma. J Soc Integr Oncol (2007) 0.80
Late effects of CNS radiation therapy. Cancer Treat Res (2009) 0.80
Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer (2013) 0.79
Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery (2005) 0.79
Laterality of brain tumors. Neuroepidemiology (2003) 0.79
The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 0.78
Proton beam stereotactic radiosurgery of vestibular schwannomas. Int J Radiat Oncol Biol Phys (2002) 0.77
It is time to reevaluate the management of patients with brain metastases. Neurosurgery (2014) 0.76
BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol (2016) 0.76
Proton beam stereotactic radiosurgery for pediatric cerebral arteriovenous malformations. Neurosurgery (2014) 0.76
Technology assessment in radiation oncology: time for reassessment? Nat Clin Pract Oncol (2008) 0.76
Response. J Neuroophthalmol (2014) 0.75
Selected human leukocyte antigen class II polymorphisms and risk of adult glioma. J Neuroimmunol (2010) 0.75
Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol (2016) 0.75
Three ways to make proton therapy affordable. Nature (2017) 0.75
811 Multimodality Treatment Approach in 424 Arteriovenous Malformations (AVMs): Improved Outcome in High Risk Lesions. Neurosurgery (2000) 0.75
Treating brain metastases: current approaches and future directions. Expert Rev Neurother (2004) 0.75
MRI changes in the rat hippocampus following proton radiosurgery. Stereotact Funct Neurosurg (2004) 0.75
Facial numbness in a man with inguinal and retroperitoneal masses. Nat Clin Pract Oncol (2005) 0.75
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-2004. A 34-year-old man with a seizure and a frontal-lobe brain lesion. N Engl J Med (2004) 0.75